Hotwire Ignite Possibility Program Introduces the First Group of Tech-enabled DEI Innovators
Hotwire, the leading global technology communications consultancy part of Enero Group, has announced the first set of participating companies in the Hotwire Ignite Possibility Program (HIPP). Launched earlier this year, HIPP is providing $1 million USD in pro bono brand marketing and public relations services to tech and tech-enabled organizations led by or supporting minority communities. This program is part of Hotwire’s Diversity, Equity, and Inclusion (DEI) strategy to amplify people and organizations creating meaningful and sustainable change in the world through technology innovation.
After a rigorous review process of nearly 100 applicants, including in-depth interviews with a short list of finalists, the first group of participating companies includes for-profit and nonprofit organizations in the consumer and B2B technology industries with headquarters in the United States and United Kingdom. HIPP participants from our other European offices and Australia will be announced in the coming months.
The six initial participating companies are:
- Children’s Creativity Musuem , a nonprofit organization offering hands-on, multimedia arts and technology experiences to build children’s creative confidence.
- Full Circle Fund , a nonprofit community leveraging professionals’ financial and intellectual capital to accelerate nonprofits and build a better San Francisco Bay Area.
- Go Flyy , an on-demand, same-day delivery and returns service for fashion, beauty and wellness products, currently operating in Los Angeles, New York City and Seattle.
- Husmus , an online service that aims to make renting easy and affordable in order to build a world where everyone can enjoy renting privately.
- Menther , a digital platform helping to empower and advance women globally through cross and intra-generational mentorship matching and support.
- Storyskimo , an online platform leveraging audio and podcasting as a language and learning development tool for children.
Additionally, as part of HIPP, our Spain office has launched an industry collaborative think tank, Margarita Bly , that is working to pave the way for more female communicators of science, technology and innovation, and encourage more girls and young women to pursue STEM careers.
“We are thrilled to announce the first class of participants in the Hotwire Ignite Possibility Program and look forward to supporting the communications goals of this impressive group of companies,” said Heather Kernahan, Global CEO, Hotwire. “This program is a critical part of Hotwire’s Diversity, Equity, and Inclusion (DEI) strategy to direct more of our resources towards the advancement of social justice in our industry.”
Teams from Hotwire’s global offices will be working with the selected organizations to address their specific business needs through customized programs that include brand strategy, marketing, and public relations services.
“We are honored to be selected as a HIPP participant and so excited to work with a world-class technology communications agency like Hotwire. Children’s Creativity Museum’s mission to nurture creativity and collaboration in all children and families, specifically those in socially and economically disadvantaged communities, is well-aligned with the program goals,” said Carol M. Tang, Ph.D., Executive Director, Children’s Creativity Museum. “We can’t wait to get started.”
“As a female minority co-founder who benefited from mentorship early on in my own career, I’m thrilled to be working with Hotwire to help us scale Menther so more women can have easy access to the power of mentorship,” said Vanessa Villaverde, Menther. “We know this partnership is going to be game changing for us in our reach and impact at a time when women who have been economically impacted by COVID-19 need support the most,” Menther Co-Founder Lesli Ott said.
“We truly believe that no matter who you are or what background you come from, you should be able to access safe and secure housing without having to worry about your credit history or the upfront costs involved,” said Sarah Wernér, Founder of Husmus. “The team and I have worked really hard to create a product that solves a big problem. However, we recognise while we have great technical experience, we do not have the marketing skills to make sure that we are able to reach the many people who need us. Working with Hotwire gives us access to expertise that we otherwise would not have at this early stage and we can’t wait to kick things off,” Husmus’ founder Sarah Wernér said.
About Hotwire
Hotwire is the global technology communication consultancy, part of the Enero Group. Founded in 2000, we operate a worldwide network of wholly owned offices and partners serving a range of clients from scale ups to established multi-nationals. We unleash the possibilities of innovative technology through integrated communications that ignite curiosity, spark action and fuel success. We do this using our proprietary methodology which is underpinned by robust insight and strategy, purposeful creative, integrated planning and a core emphasis on measurement and evaluation. www.hotwireglobal.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210630005248/en/
Contact information
Kelsey Quickstad
kelsey.quickstad@hotwireglobal.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Crown Bioscience Expands US Presence with New Model Development Center in Kannapolis, North Carolina17.9.2025 15:30:00 EEST | Press release
Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, today announced the opening of a state-of-the-art model development center in Kannapolis, North Carolina. This strategic investment expands the company’s operations and enhances its ability to deliver advanced preclinical oncology models, including patient-derived xenografts (PDX), PDX warm models, PDX-derived organoids (PDXO), and patient-derived organoids (PDO), to meet the evolving needs of pharmaceutical and biotechnology companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917864004/en/ Crown Bioscience celebrate the official ribbon-cutting ceremony for the company’s new Kannapolis, North Carolina facility, marking an expansion of US oncology model development and preclinical CRO services. The new facility strengthens Crown Bioscience’s US-based capabil
SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment17.9.2025 15:00:00 EEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced the launch of a new brand, “Hada no Aozora Clinic”, scheduled to open in Tokyo on October 1, 2025. This clinic will adopt a hybrid dermatology model that integrates insurance-covered general dermatology and private-pay aesthetic treatments, advancing SBC’s multi-brand strategy in the rapidly expanding aesthetic medicine market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917897380/en/ SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment As life expectancy continues to rise and demographic aging accelerates, more people are seeking treatments that help them maintain both well-being and a youthful appearance over a longer lifespan. Within this environment, aesth
Merck to Present New Data Highlighting Durable Effects of MAVENCLAD ® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 202517.9.2025 15:00:00 EEST | Press release
Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of over 30 abstracts from its multiple sclerosis (MS) portfolio. New four-year data from two large Phase 4 studies highlight the long-term efficacy, favorable disability outcomes and durable impact of MAVENCLAD® (cladribine tablets) in people living with relapsing multiple sclerosis (RMS). These findings are to be presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held September 24-26 in Barcelona. “As the only high-efficacy short-course oral treatment, MAVENCLAD has demonstrated sustained benefits across a variety of outcomes—extending beyond relapses and MRI—without requiring continuous immunosuppression,” said Alex Kulla, Senior Vice President & Global Head of the Neurology & Immunology Medical Unit for the Healthcare business of Merck. “With over two decades of clinical experience an
Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis, Expands Clinical Advisory Board17.9.2025 15:00:00 EEST | Press release
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase 1b/2a study with lead drug candidate RLS-1496 in patients with actinic keratosis. RLS-1496 is a first-in-class disease-modifying selective glutathione peroxidase 4 (GPX4) modulator targeting pathological senescent cells that drive inflammaging and chronic degenerative diseases and conditions associated with the biological aging process. The study is expected to begin in Q4 2025. The first EMA-cleared RLS-1496 clinical trial began in May 2025 for plaque psoriasis, atopic dermatitis, and skin aging (photoaged skin); study results are expected in Q4 2025. Actinic keratosis is a rough, scaly patch caused by sun exposure that appears on sun-exposed areas of the skin, such as
New Study Finds That Using Masimo Technologies to Continuously Monitor General Floor Patients Reduces Costs17.9.2025 15:00:00 EEST | Press release
Masimo (NASDAQ: MASI) today announced the findings of a study published in the Journal of Patient Safety in which Dr. George Blike and colleagues at Dartmouth-Hitchcock Medical Center in New Hampshire demonstrated that use of Masimo technologies to continuously monitor general floor patients can yield significant cost savings.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917266545/en/ Continuous Patient Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ In prior studies, the clinical outcome benefits of continuously monitoring patients using Masimo SET® and Patient SafetyNet™ have been shown to include lower mortality, improved resuscitative outcomes, and fewer rapid response team activations and transfers to higher-acuity care units, achieved through earlier detection and intervention to prevent patient deterioration.2-5 Now, in this new retrospective analysis – involving 3-1/2 years of data and almost
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom